Kyrgyzstan Medical Device Registration Documents: Power of Attorney Notarization and Legalization Chain
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Foreign documents required for registration in Kyrgyzstan must pass through a fixed processing chain: original document, notarization, legalization, translation. The order cannot be reversed. If translation precedes legalization, the legalization authority certifies the translated text rather than the validity of the original, and this is generally not accepted. The most common failures on this chain are not individual steps but problems of sequence and consistency: the manufacturer name and address on the power of attorney, the free sale certificate, and the quality system certificate must match the application form and the labeling word for word.
2. Legal basis
- Cabinet Resolution No. 513, August 27, 2024, Annex 1, Article 2: the authorized representative of a manufacturer must be empowered under the power of attorney of the manufacturer.
- Law No. 216, Article 14: foreign products must have confirmation that they circulate as medical devices in the manufacturing country or in other countries.
- Public forms of the competent authority: Annex 1 (registration application form) and Annex 10 (declaration of responsibility for the truthfulness of information).
- Law No. 216, Article 15: providing false information constitutes a ground for revocation of the registration certificate.
Source note: the specific formal requirements for notarization and legalization, including the accepted legalization method, whether translated documents must be notarized again, and the number of copies accepted, were not available this cycle in official detail capable of verbatim citation. The statements below are a practical estimate; in actual processing, the acceptance requirements of the competent authority prevail.
3. Expert insights
Insight 1: the price of a wrong sequence is redoing the entire chain.
There are two typical wrong sequences. The first is translating before legalizing: the legalization authority certifies the translation, yet the legal effect of a translation depends on the original, so the object of legalization is misplaced. The second is legalizing before completing notarization: legalization is a second-tier confirmation built on notarization, and without the preceding notarization it has no foundation. The consequence of either error is redoing the whole chain, with a double loss of time and money.
Insight 2: the signatories of the power of attorney and the declaration of responsibility must sit within the same chain of authorization.
The power of attorney empowers the authorized representative to act, while the declaration of responsibility in Annex 10 is signed by the applicant. The signing parties of the two documents should fall within the same authorization chain; otherwise situations can arise in which the filer is entitled to submit but not to bear responsibility, or the reverse. We recommend confirming the signing authority for the declaration of responsibility at the same time as the power of attorney is executed.
Insight 3: consistency checks must cover wording, not just substance.
Common inconsistencies are not misspelled names but differences in rendering: the abbreviation style of the English name of the manufacturer, the format of street numbers and floors in the address, and the transliteration of city names. These differences are trivial in a Chinese-language context, but at acceptance they are enough to trigger a request for correction. We recommend building a standard wording table that fixes the Russian rendering of the manufacturer name and address, cited uniformly across all documents.
Insight 4: document validity periods must match the project timeline.
Free sale certificates, quality system certificates, and powers of attorney each carry their own validity period. If a document expires while the project is in progress, an updated document will be required. We recommend aligning validity periods before project launch and choosing to execute documents at a point where validity is ample; for the power of attorney, we recommend setting a long authorization term (see Part 22 of this series).
Insight 5: executing multiple originals at once is more economical than repeated follow-up runs.
The processing time for notarization and legalization cannot be compressed, and each run carries a fixed cost. We recommend executing a sufficient number of originals in one batch at project start, normally covering five uses: the registration application, change applications, import declarations, inspection cooperation, and archival backup. This avoids repeated follow-up runs later.
4. Practical recommendations
First, write the chain sequence into the project procedure documents. We recommend marking the sequence explicitly in the standard operating procedure: original, notarization, legalization, translation, internal review, five steps in strict order, with each step completed and archived before the next begins.
Second, build a standard wording table and cite it across the project. We recommend fixing the Russian rendering of the manufacturer name, address, product names, and models, and citing this table uniformly in all outbound documents.
Third, confirm signing authority in parallel. We recommend verifying, when executing the power of attorney, that the signatory of the Annex 10 declaration of responsibility acts within the scope of authorization, and issuing proof of signing authority where necessary.
Fourth, check validity periods and choose execution windows with ample margin. We recommend aligning document validity periods with the project timeline before execution to avoid mid-project expiry; set a long authorization term for the power of attorney with automatic renewal.
Fifth, execute a sufficient number of copies in one batch. We recommend estimating the number of copies against the five uses of registration, changes, import, inspection, and archiving, and completing all of them at once.
5. Verification checklist
- □ Processing chain sequence is correct: original, notarization, legalization, translation, internal review;
- □ The signatories of the power of attorney and the Annex 10 declaration of responsibility sit within the same authorization chain;
- □ A standard wording table has been established fixing the Russian rendering of the manufacturer name, address, product names, and models;
- □ Validity periods of the power of attorney, free sale certificate, and quality system certificate have been checked against the project timeline;
- □ The authorization term of the power of attorney is ample, with automatic renewal agreed;
- □ A sufficient number of copies has been executed in one batch for the five uses of registration, changes, import, inspection, and archiving.
Regulatory information verified as of October 29, 2026.
Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance coaching, post-market surveillance and vigilance system setup, import and distribution compliance, state fee estimation, and project budget management.
The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. It maintains a stable local cooperation network in Bishkek, Almaty, Tashkent, Moscow, and other cities, and works in Chinese, Russian, and English. For the key issues that foreign manufacturers commonly face in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection response, GRZAN provides executable solutions.
We hold to one principle: every regulatory conclusion we publish must be traceable to verifiable official sources. Any figure or timeline that cannot be verified is always labeled as a practical estimate, and experience values are never presented as legal grounds.
GRZAN provides registration and compliance support in Kyrgyzstan for medical device manufacturers, importers, and authorized representatives. For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.
GRZAN | Global Medical Device Regulatory Registration and Compliance Services
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us